May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
May 2011 in “Journal of The American Academy of Dermatology” Objective assessment is needed to accurately determine medication use and adherence.
33 citations
,
January 2019 in “Acta Dermato Venereologica” Dupilumab may help regrow hair in people with atopic dermatitis.
September 2018 in “Dermatologic Surgery”
Individualized treatments may help manage Dercum's disease symptoms.
8 citations
,
November 2019 in “International Journal of Pharmaceutics” The method improves acne treatment by enhancing drug delivery and reducing skin irritation.
November 2025 in “JEADV Clinical Practice” Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.
6 citations
,
November 2020 in “JAAD Case Reports” Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
September 2025 in “The health sciences AUS.” Intralesional triamcinolone acetonide effectively treats acne keloidalis nuchae with minimal side effects.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
5 citations
,
July 2020 in “Journal of the American Academy of Dermatology” Adding antihistamines to topical corticosteroid and cryotherapy may improve hair regrowth in alopecia areata patients.
January 2024 in “JAAD case reports” MSUD patients need careful monitoring of amino acids and zinc to prevent severe symptoms.
8 citations
,
January 2020 in “Indian Dermatology Online Journal” PRP works faster and is a safe alternative to steroids for treating alopecia areata.
December 2025 in “International Journal of Dermatology” Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
49 citations
,
December 2018 in “JAAD case reports” Dupilumab may cause significant hair loss, which can reverse after stopping the drug.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
March 2025 in “Dermatologic Surgery” Fractional radiofrequency microneedling is as effective and safe as intralesional steroids for treating patchy alopecia areata, with fewer side effects.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
7 citations
,
July 2019 in “International journal of research in dermatology” Intralesional triamcinolone acetonide is more effective than platelet-rich plasma for treating scalp alopecia areata.
July 2025 in “Journal of Investigative Dermatology” AMP-303 safely increases hair growth in men with hair loss.
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab is safe for long-term use with low rates of major heart-related events.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
15 citations
,
March 2008 in “The Journal of Dermatology” Topical squaric acid dibutylester worsened discoid lupus erythematosus in a patient.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
Belimumab may cause hair loss in lupus patients.